文献速递产科母胎医学

无创产前细胞游离DNA筛查结果不可报告相关的产科、围产期及遗传结局

Obstetrical, perinatal, and genetic outcomes associated with nonreportable prenatal cell-free DNA screening results.
PubMed 文献 · Am J Obstet Gynecol · 2023-03-23

这项多中心前瞻性观察研究的预设二次分析纳入17,851名接受产前细胞游离DNA筛查的孕妇,其中602例(3.4%)结果不可报告。结果不可报告与染色体非整倍体、子痫前期、早产及复合不良结局风险升高相关,活产率降低。作者建议为这些患者提供诊断性遗传检测,并提醒临床医生注意妊娠并发症风险增加。

要点

  • 无创产前细胞游离DNA筛查结果不可报告者占3.4%,与更高的体重指数、慢性高血压、更晚的孕周、更低的胎儿分数及黑人种族相关。
  • 结果不可报告者中13、18或21三体确认率为1.6%,显著高于结果可报告者的0.7%(P=.013)。
  • 首次和第二次结果不可报告后,复合不良结局的调整比值比分别为1.5(95%CI 1.2-1.8)和2.1(95%CI 1.4-3.2)。

核心结论

  • 细胞游离DNA结果不可报告的患者面临多种不良结局风险增加,包括非整倍体、子痫前期和早产。
  • 作者建议为这些患者提供诊断性遗传检测,临床医生应意识到妊娠并发症风险增加。

研究设计与样本

  • 这是一项多中心前瞻性观察研究的预设二次分析,研究产前细胞游离DNA筛查对胎儿非整倍体和22q11.2缺失综合征的检测。
  • 2015年4月至2019年1月期间接受细胞游离DNA筛查的参与者被邀请参加,来自美国、欧洲和澳大利亚的21个初级保健和转诊中心。
  • 最终研究队列包括17,851名(88.4%)参与者,具有细胞游离DNA、胎儿或新生儿遗传确认检测以及产科和围产期结局数据。

主要发现

  • 在25,199名筛查孕妇中,20,194名入组,最终17,851名(88.4%)纳入分析;602名(3.4%)结果不可报告。
  • 427名重新采血再次检测,其中112名(26.2%)结果再次不可报告。
  • 结果不可报告者中13、18或21三体确认率为1.6%,结果可报告者为0.7%(P=.013)。
  • 调整混杂因素后,首次和第二次结果不可报告后非整倍体的调整比值比分别为2.2(95%CI 1.1-4.4)和2.6(95%CI 0.6-10.8),复合结局的调整比值比分别为1.5(95%CI 1.2-1.8)和2.1(95%CI 1.4-3.2)。
  • 结果不可报告者活产率为94.9%,结果可报告者为98.8%(活产调整比值比0.20 [95%CI 0.13-0.30])。

临床怎么用

  • 作者建议为细胞游离DNA结果不可报告的患者提供诊断性遗传检测,临床医生应意识到妊娠并发症风险增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical implications of nonreportable cell-free DNA screening results are uncertain, but such results may indicate poor placental implantation in some cases and be associated with adverse obstetrical and perinatal outcomes. OBJECTIVE: This study aimed to assess the outcomes of pregnancies with nonreportable cell-free DNA screening in a cohort of patients with complete genetic and obstetrical outcomes. STUDY DESIGN: This was a prespecified secondary analysis of a multicenter prospective observational study of prenatal cell-free DNA screening for fetal aneuploidy and 22q11.2 deletion syndrome. Participants who underwent cell-free DNA screening from April 2015 through January 2019 were offered participation. Obstetrical outcomes and neonatal genetic testing results were collected from 21 primary-care and referral centers in the United States, Europe, and Australia. The primary outcome was risk for adverse obstetrical and perinatal outcomes (aneuploidy, preterm birth at <28, <34, and <37 weeks' gestation, preeclampsia, small for gestational age or birthweight <10th percentile for gestational week, and a composite outcome that included preterm birth at <37 weeks, preeclampsia, small for gestational age, and stillbirth at >20 weeks) after nonreportable cell-free DNA screening because of low fetal fraction or other causes. Multivariable analyses were performed, adjusting for variables known to be associated with obstetrical and perinatal outcomes, nonreportable results, or fetal fraction. RESULTS: In total, 25,199 pregnant individuals were screened, and 20,194 were enrolled. Genetic confirmation was missing in 1165 (5.8%), 1085 (5.4%) were lost to follow-up, and 93 (0.5%) withdrew; the final study cohort included 17,851 (88.4%) participants who had cell-free DNA, fetal or newborn genetic confirmatory testing, and obstetrical and perinatal outcomes collected. Results were nonreportable in 602 (3.4%) participants. A sample was redrawn and testing attempted again in 427; in 112 (26.2%) participants, results were again nonreportable. Nonreportable results were associated with higher body mass index, chronic hypertension, later gestational age, lower fetal fraction, and Black race. Trisomy 13, 18, or 21 was confirmed in 1.6% with nonreportable tests vs 0.7% with reported results (P=.013). Rates of preterm birth at <28, 34, and 37 weeks, preeclampsia, and the composite outcome were higher among participants with nonreportable results, and further increased among those with a second nonreportable test, whereas the rate of small for gestational age infants was not increased. After adjustment for confounders, the adjusted odds ratios were 2.2 (95% confidence interval, 1.1-4.4) and 2.6 (95% confidence interval, 0.6-10.8) for aneuploidy, and 1.5 (95% confidence interval, 1.2-1.8) and 2.1 (95% confidence interval, 1.4-3.2) for the composite outcome after a first and second nonreportable test, respectively. Of the patients with nonreportable tests, 94.9% had a live birth, as opposed to 98.8% of those with reported test results (adjusted odds ratio for livebirth, 0.20 [95% confidence interval, 0.13-0.30]). CONCLUSION: Patients with nonreportable cell-free DNA results are at increased risk for a number of adverse outcomes, including aneuploidy, preeclampsia, and preterm birth. They should be offered diagnostic genetic testing, and clinicians should be aware of the increased risk of pregnancy complications.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Norton ME, MacPherson C, Demko Z, et al. Obstetrical, perinatal, and genetic outcomes associated with nonreportable prenatal cell-free DNA screening results. Am J Obstet Gynecol. 2023. PMID: 36965866. doi:10.1016/j.ajog.2023.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。